News

Categories

January 25, 2023

Zymeworks Announces Participation In Upcoming Investor Conferences

January 19, 2023

Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

January 4, 2023

Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023

December 21, 2022

Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab

December 19, 2022

Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab

December 14, 2022

Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

December 9, 2022

New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS

November 21, 2022

Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Metastatic Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS)

October 20, 2022

Zymeworks Early R&D Day Highlights Progress In Development Of Novel Pipeline Assets And Applications Of Proprietary Next-Generation Technology Platforms

October 19, 2022

Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody

October 4, 2022

Zymeworks Announces Participation In Upcoming Investor Conferences And Early Research & Development Day

September 4, 2022

Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers